Determinants of early childhood asthma and atopy following infant RSV infection

婴儿 RSV 感染后儿童早期哮喘和特应性的决定因素

基本信息

  • 批准号:
    8511345
  • 负责人:
  • 金额:
    $ 21.87万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY (See instructions): PROJECT 1: RSV bronchiolitis and early childhood asthma are the most common, serious, acute, and chronic conditions of infancy and childhood, respectively, and diseases that disproportionately burden vulnerable populations. Opportunity and Impact. This project draws together three important elements in understanding the role of RSV on recurrent wheezing and asthma inception - RSV infection severity, host response and susceptibility. In studying the association of RSV with asthma inception, studies have overwhelmingly focused on the 3-5% of RSV-infected infants requiring hospitalization, while the vast majority of RSV infections are mild. Whether mild infection confers intermediate risk or has a protective effect is an important question. The answer will influence proposals for primary asthma prevention strategies. The proposed series of investigations will aid in our understanding of the role and mechanisms through which RSV may both lead to chronic lung disease, and may protect from chronic lung disease. Approach. Utilizing the ReSPIRA cohort, established for this investigation and described in Core B, we will investigate the relationship between infant RSV infection, host response to infection, and genetic determinants of recurrent wheezing, asthma and allergic disease development following RSV infection. Our specific aims are to: (1) Establish the association between RSV LRTI, RSV URI/exposure, and no RSV infection in the first 6 months of life on the risk of recurrent wheezing and asthma, (2) Define whether host immune response and/or airway injury biomarkers assessed during infant RSV infection are associated with recurrent wheezing, atopic disease or early childhood asthma, and (3) Identify the genetic determinants of the phenotype of recurrent wheezing, early childhood asthma and atopy following infant RSV infection. Utilizing the ReSPIRA cohort which includes 2000 infants followed from early infancy through early childhood, and established through this U19 grant, this project will answer the following questions: (1) how does RSV cause asthma, (2) does mild RSV infection during infancy increase or decrease the risk of asthma, and (3) what host factors are important in the progression from infant RSV infection to early childhood asthma. Answering these questions will allow us to develop preventive interventions for chronic lung disease in children, and ultimately improve the health of infants and children with bronchiolitis and asthma in the U.S. and worldwide.
项目总结(见说明): 项目1:RSV细支气管炎和幼儿哮喘分别是婴儿期和儿童期最常见、最严重、最急性和最慢性的疾病,也是给弱势群体造成不成比例负担的疾病。 机会和影响。该项目汇集了三个重要因素,以了解RSV在反复喘息和哮喘发病中的作用- RSV感染严重程度,宿主反应和易感性。 在研究RSV与哮喘发病的相关性时,研究主要集中在3-5%的RSV感染婴儿需要住院治疗,而绝大多数RSV感染是轻度的。轻度感染是否具有中等风险或具有保护作用是一个重要的问题。这个问题的答案将影响哮喘初级预防策略的建议。拟议的一系列调查将有助于我们了解RSV可能导致慢性肺部疾病的作用和机制,并可能防止慢性肺部疾病。 Approach.利用ReSPIRA队列(为本研究建立并在核心B中描述),我们将研究婴儿RSV感染、宿主对感染的反应以及RSV感染后复发性喘息、哮喘和过敏性疾病发展的遗传决定因素之间的关系。我们的具体目标是:(1)建立RSV LRTI、RSV URI/暴露和出生后前6个月内无RSV感染与复发性喘息和哮喘风险之间的关联,(2)确定婴儿RSV感染期间评估的宿主免疫应答和/或气道损伤生物标志物是否与复发性喘息、特应性疾病或早期儿童哮喘相关,(3)确定RSV感染后反复喘息、儿童早期哮喘和特应性表型的遗传决定因素。 利用ReSPIRA队列,其中包括2000名从婴儿早期到幼儿期的婴儿,并通过U19赠款建立,该项目将回答以下问题:(1)RSV如何引起哮喘,(2)婴儿期轻度RSV感染是否增加或减少哮喘的风险,以及(3)在婴儿RSV感染发展为儿童早期哮喘的过程中,哪些宿主因素是重要的。解决这些问题将使我们能够开发儿童慢性肺部疾病的预防干预措施,并最终改善美国和世界各地患有细支气管炎和哮喘的婴儿和儿童的健康。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tina V Hartert其他文献

Tina V Hartert的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tina V Hartert', 18)}}的其他基金

ECHO Renewal for the CANOE Study Cohort
CANOE 研究队列的 ECHO 更新
  • 批准号:
    10745082
  • 财政年份:
    2023
  • 资助金额:
    $ 21.87万
  • 项目类别:
Identifying Asthma-causing RSV Strains and Elucidating the Mechanisms of RSV-mediated Asthma Development
鉴定引起哮喘的 RSV 菌株并阐明 RSV 介导的哮喘发展机制
  • 批准号:
    10230392
  • 财政年份:
    2020
  • 资助金额:
    $ 21.87万
  • 项目类别:
Identifying Asthma-causing RSV Strains and Elucidating the Mechanisms of RSV-mediated Asthma Development
鉴定引起哮喘的 RSV 菌株并阐明 RSV 介导的哮喘发展机制
  • 批准号:
    10301922
  • 财政年份:
    2020
  • 资助金额:
    $ 21.87万
  • 项目类别:
Newborn Metabolic Screening for Prediction of Childhood Respiratory Phenotypes
新生儿代谢筛查用于预测儿童呼吸表型
  • 批准号:
    9090671
  • 财政年份:
    2016
  • 资助金额:
    $ 21.87万
  • 项目类别:
Newborn Metabolic Screening for Prediction of Childhood Respiratory Phenotypes
新生儿代谢筛查用于预测儿童呼吸表型
  • 批准号:
    9250797
  • 财政年份:
    2016
  • 资助金额:
    $ 21.87万
  • 项目类别:
Clinical Ascertainment, Biospecimen Acquisition, Data Management and Analysis Research Core
临床确定、生物样本采集、数据管理和分析研究核心
  • 批准号:
    10460524
  • 财政年份:
    2011
  • 资助金额:
    $ 21.87万
  • 项目类别:
Identifying Asthma-causing RSV Strains and Elucidating the Mechanisms of RSV-mediated Asthma Development
鉴定引起哮喘的 RSV 菌株并阐明 RSV 介导的哮喘发展机制
  • 批准号:
    9975086
  • 财政年份:
    2011
  • 资助金额:
    $ 21.87万
  • 项目类别:
Clinical Ascertainment, Biospecimen Acquisition, Data Management and Analysis Research Core
临床确定、生物样本采集、数据管理和分析研究核心
  • 批准号:
    10262868
  • 财政年份:
    2011
  • 资助金额:
    $ 21.87万
  • 项目类别:
RSV to Asthma Cooperative Clinical Ascertainment and Biospecimen Research Core
RSV 与哮喘合作临床确定和生物样本研究核心
  • 批准号:
    8196536
  • 财政年份:
    2011
  • 资助金额:
    $ 21.87万
  • 项目类别:
Clinical Ascertainment, Biospecimen Acquisition, Data Management and Analysis Research Core
临床确定、生物样本采集、数据管理和分析研究核心
  • 批准号:
    10675721
  • 财政年份:
    2011
  • 资助金额:
    $ 21.87万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 21.87万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.87万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 21.87万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.87万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 21.87万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.87万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 21.87万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 21.87万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 21.87万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.87万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了